Researchers are investigating the potential benefits of using inexpensive statins to extend the lifespan of individuals with motor neurone disease (MND), a condition that typically leads to death within three to five years of diagnosis. MND, a progressive neurodegenerative disease characterized by muscle weakness, currently has no cure. However, a study led by experts at Stanford University in the US delved into the medical records of 11,003 veterans diagnosed with amyotrophic lateral sclerosis (ALS), a form of MND, between 2009 and 2019.

The analysis revealed that individuals prescribed certain medications, including statins for high cholesterol and alpha blockers for urinary issues in men with enlarged prostates, tended to have longer survival rates. The study, published in the Lancet Digital Health journal, highlighted 18 medications associated with prolonged survival, suggesting a potential repurposing of these drugs for ALS treatment.

Lead researcher Professor Richard Reimer from Stanford University School of Medicine emphasized the lack of effective ALS treatments, leading to a short life expectancy post-diagnosis. The study’s findings propose that statins and alpha blockers could potentially enhance survival rates for ALS patients, considering these medications are widely available in cost-effective generic forms and are generally well-tolerated.

Moving forward, the researchers aim to investigate the underlying reasons behind the observed associations and identify the specific groups that may benefit from these treatments. Understanding the mechanisms by which statins and alpha blockers influence ALS survival rates could pave the way for future placebo-controlled trials to validate their effectiveness.

Notably, actor Eric Dane, known for his role as Dr. Mark ‘McSteamy’ Sloan on Grey’s Anatomy, passed away in February at 53 after publicly disclosing his ALS diagnosis. Dane, who later appeared in the HBO series Euphoria, had become a vocal advocate for the ALS community following his diagnosis.